Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research(2022)
摘要
Combining niraparib with Radium-223 in patients with mCRPC was safe however further studies incorporating biomarkers will better elucidate the role of combinations of PARP inhibitors with DNA damaging and other agents.
更多查看译文
关键词
prostate cancer,niraparib,castrate-resistant
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要